EOLS Evolus Inc.

4.57
-0.73  -14%
Previous Close 5.3
Open 5.31
Price To Book 2.46
Market Cap 154,139,144
Shares 33,728,478
Volume 2,000,780
Short Ratio
Av. Daily Volume 837,783
Stock charts supplied by TradingView

NewsSee all news

  1. Evolus Reports First Quarter 2020 Results and Provides Business Update

    NEWPORT BEACH, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial

  2. Evolus to Report First Quarter 2020 Financial Results and Provide a Business Update on Monday, May 11, 2020

    NEWPORT BEACH, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it

  3. Evolus Provides Strategic Business Update

    NEWPORT BEACH, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced a

  4. Evolus Provides Update on International Trade Commission (ITC) Case

    NEWPORT BEACH, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) today provided the following statement: "In several media reports this week, Medytox has made comments on the International Trade

  5. Evolus to Participate in Barclays 2020 Global Healthcare Conference

    NEWPORT BEACH, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Approval announced February 1, 2019.
DWP-450
Glabellar lines

Latest News

  1. Evolus Reports First Quarter 2020 Results and Provides Business Update

    NEWPORT BEACH, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial

  2. Evolus to Report First Quarter 2020 Financial Results and Provide a Business Update on Monday, May 11, 2020

    NEWPORT BEACH, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it

  3. Evolus Provides Strategic Business Update

    NEWPORT BEACH, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced a

  4. Evolus Provides Update on International Trade Commission (ITC) Case

    NEWPORT BEACH, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) today provided the following statement: "In several media reports this week, Medytox has made comments on the International Trade

  5. Evolus to Participate in Barclays 2020 Global Healthcare Conference

    NEWPORT BEACH, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that

  6. Evolus Reports Fourth Quarter and Full Year 2019 Results and Provides Business Update

    Q4 2019 Net Revenue $19.5 Million, Up from $13.2 Million in Q3 2019 Jeuveau® Achieved Number Three Unit Share Position in the U.S. in 20191 Launched Evolux™; Only Practice Loyalty Program to Offer

  7. Evolus to Participate in 9th Annual SVB Leerink Global Healthcare Conference

    NEWPORT BEACH, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that

  8. Evolus to Report Fourth Quarter and Full Year 2019 Financial Results and Provide a Business Update on Tuesday, February 25, 2020

    NEWPORT BEACH, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it

  9. Positive Results from Phase III, Split-Face, Head-to-Head Study Comparing OnabotulinumtoxinA and PrabotulinumtoxinA in the Treatment of Crow's Feet Lines Published in Dermatologic Surgery

    NEWPORT BEACH, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the

  10. ALPHAEON Corporation Completes Reorganization to Simplify its Corporate Structure

    ALPHAEON Corporation ("ALPHAEON"), announced today that it has completed a reorganization to simplify its corporate structure. As a result of this reorganization the company has split into two business units, each of

  11. Evolus Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenue

    Q4 2019 net revenue estimated between $18.5 and $19.5 million; increased from $13.2 million in Q3 2019 Completed Q4 2019 with over 3,500 purchasing accounts; increased from over 2,000 at end of Q3 2019

  12. Evolus to Participate in Stifel Healthcare Conference

    NEWPORT BEACH, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that

  13. Evolus Announces Pricing of Public Offering of Common Stock

    NEWPORT BEACH, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) ("Evolus") announced today the pricing of its public offering of 5,217,000 shares of its common stock at a public offering price of

  14. Evolus Announces Proposed Public Offering of Common Stock

    NEWPORT BEACH, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) ("Evolus") announced today that it has commenced a proposed underwritten public offering, subject to market and other conditions, to

  15. Evolus Reports Third Quarter 2019 Financial Results and Provides Business Update

    Jeuveau® Generated $13.2 Million in U.S. Net Revenue in Q3 2019; up from $2.3 Million in Q2 2019 J.E.T. Enrolled Accounts Drove 90% of Q3 Revenue Jeuveau® Achieved Number Three Unit Share Position in

  16. Evolus to Report Third Quarter 2019 Financial Results and Provide a Business Update on Monday, November 4, 2019

    NEWPORT BEACH, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it

  17. Evolus Receives Approval for Nuceiva™ in the European Union

    NEWPORT BEACH, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that the

  18. Evolus will Participate in Cantor Global Healthcare Conference

    NEWPORT BEACH, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that

  19. Evolus Announces Successful Completion of the Jeuveau® Experience Treatment (J.E.T) Program

    Jeuveau® Achieves Number Three Unit Share Position1 in the U.S. Within 90 Days of Launch NEWPORT BEACH, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a

  20. Evolus to Participate in Two Upcoming Investor Conferences

    NEWPORT BEACH, Calif., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that